A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders.

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Abstract Text:

Brain-derived neurotrophic factor (BDNF) has been studied extensively in relation to the susceptibility to mood disorders (MD), although it remains to be clarified whether BDNF is a susceptibility locus for MD phenotypes, including therapeutic response to antidepressants. We have performed a single-marker and haplotype association study of eight TagSNPs polymorphisms in the genomic region containing the BDNF gene in 342 control subjects and 374 patients with MD, and have tested the association with antidepressant treatment outcome. None of the eight single nucleotide polymorphisms (TagSNPs) was significantly associated with MD phenotype after Bonferroni correction. In the single-marker analysis, a SNP was found to be associated with the patient's state of 'remitter' after adequate trial with a single antidepressant phenotype (odds ratio (OR)=2.95; P=0.0025). We also identified a haplotype associated with this phenotype. This study supports the implication of BDNF in antidepressant treatment outcome in MD, with specific association with 5' upstream region of BDNF gene.The Pharmacogenomics Journal (2008) 8, 101-112; doi:10.1038/sj.tpj.6500460; published online 15 May 2007.

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The pharmacogenomics journal

VOLUME: 8

Page Numbers: 101-12

Journal Abbreviation: Pharmacogenomics J.

ISSN: 1470-269X

DAY: 15

MONTH: 05

YEAR: 2007

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101083949

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders.

AFFILIATION: 1Genes and Disease Program, and CeGen Barcelona Genotyping Node, Center for Genomic Regulation (CRG), Barcelona, Spain.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pharmacogenomics J

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A brain-derived neurotrophic factor BDNF haplotype is associated with antidepressant treatment outcome in mood disorders Related Publications

• A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders.
• A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart.
• Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia.
• Alu-splice PCR: a simple method to isolate exon-containing fragments from cloned human genomic DNA.
• Analysis of the multi-copy gene family FAM90A as a copy number variant in different ethnic backgrounds.
• Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders.
• Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients.
• Characterization and evolution of the novel gene family FAM90A in primates originated by multiple duplication and rearrangement events.
• Contribution of the serotoninergic system to anxious and depressive traits that may be partially responsible for the phenotypical variability of bulimia nervosa.
• Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations.
• Extensive Genotyping of the BDNF and NTRK2 Genes Define Protective Haplotypes Against Obsessive-Compulsive Disorder.
• Functional genomics of Down syndrome: a multidisciplinary approach.
• Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene.
• Identification of two new nonsense mutations (Q311X and W326X) in Exon 2 of the adrenoleukodystrophy (ALD) gene.
• MRPS18CP2 alleles and DEFA3 absence as putative chromosome 8p23.1 modifiers of hearing loss due to mtDNA mutation A1555G in the 12S rRNA gene.
• Probe-specific mixed-model approach to detect copy number differences using multiplex ligation-dependent probe amplification (MLPA).
• Recurrence of the PKD1 nonsense mutation Q4041X in Spanish, Italian, and British families.
• Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin.
• [Large-scale genotyping in research into autism spectrum disorders and attention deficit hyperactivity disorder.]